Limited Survival Benefit of Short-Course Neoadjuvant Gemcitabine Plus Nab-Paclitaxel for Resectable Pancreatic Cancer: A Prospective Phase II Study With a Propensity Score–Matched Analysis
Limited Survival Benefit of Short-Course Neoadjuvant Gemcitabine Plus Nab-Paclitaxel for Resectable Pancreatic Cancer: A Prospective Phase II Study With a Propensity Score–Matched Analysis. // Journal of Surgical Research. – URL: https://www.sciencedirect.com/science/article/pii/S0022480426005731?dgcid=rss_sd_all
Limited Survival Benefit of Short-Course Neoadjuvant Gemcitabine Plus Nab-Paclitaxel for Resectable Pancreatic Cancer: A Prospective Phase II Study With a Propensity Score–Matched Analysis. Journal of Surgical Research. https://www.sciencedirect.com/science/article/pii/S0022480426005731?dgcid=rss_sd_all
“Limited Survival Benefit of Short-Course Neoadjuvant Gemcitabine Plus Nab-Paclitaxel for Resectable Pancreatic Cancer: A Prospective Phase II Study With a Propensity Score–Matched Analysis.” Journal of Surgical Research.
@article{article55636,
title = {Limited Survival Benefit of Short-Course Neoadjuvant Gemcitabine Plus Nab-Paclitaxel for Resectable Pancreatic Cancer: A Prospective Phase II Study With a Propensity Score–Matched Analysis},
journal = {Journal of Surgical Research},
url = {https://www.sciencedirect.com/science/article/pii/S0022480426005731?dgcid=rss_sd_all}
}